Remove 2018 Remove Dosage Remove Drug Pricing
article thumbnail

Price Limits, Affordability Boards, Penalties, Oh My: Minnesota Enacts Sweeping Drug Pricing Reforms

FDA Law Blog: Biosimilars

Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers.

article thumbnail

Happy 40th Anniversary Hatch-Waxman! We’re Celebrating By Providing Access to a New Archive

FDA Law Blog: Biosimilars

Hatch Foundation’s For cheap generic drug prices, you can thank 40 years of Hatch-Waxman We Work For Health’s Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem Tradeoffs’ Race to the Bottom Series FDA CDER Conversations – 40th Anniversary of the Generic Drug Approval Pathway The U.S.

Dosage 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

Last week, Novartis announced plans to pay $245 million to end a pay-for-delay legal battle that started in 2018. In this most recent settlement, the drug company faced allegations of colluding with the generics company Par Pharmaceuticals to violate antitrust laws. These actions allegedly led to the extension of Novartis’ patents.

article thumbnail

ProxsysRx’s MedServRx: The Prescription-Drug Advantage For Patients And Their Providers

Proxsys Rx

As with other discount cards, patients can use their provider’s easy-to-use MedServRx website to search — and compare prices among participating local pharmacies — for drugs by name. This added search capability gives patients the advantage of true price comparison based on their individual needs.

article thumbnail

Sandoz spin-off continues Novartis’ focus on innovation; $22bn purchase rumoured

Pharmaceutical Technology

Novartis said in August that it intended to shut down its Sandoz oral solid dosage plant in Wilson, North Carolina, which provides tablets to Canada and the US, next year. Innovative drug development can be costly and risky due to clinical trial attrition of unproven drugs, but can provide a high return on investment when successful.